Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia

Journal of Clinical Oncology

Volumn 26, Issue 31, 2008, Pages 5088-5093

  Pabst, Thomas ^a   Eyholzer, Marianne ^a   Haefliger, Simon ^a   Schardt, Julian ^a   Mueller, Beatrice U ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DNA; HYDROXYUREA;

ACUTE GRANULOCYTIC LEUKEMIA; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CARBOXY TERMINAL SEQUENCE; CEBPA GENE; DNA DETERMINATION; FAMILIAL DISEASE; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC SCREENING; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOSOMY; MYELOABLATIVE CONDITIONING; POINT MUTATION; PRIORITY JOURNAL; REMISSION; SOMATIC MUTATION;

ADOLESCENT; ADULT; CCAAT-ENHANCER-BINDING PROTEINS; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, LEUKEMIC; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HETEROZYGOTE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PEDIGREE; RISK FACTORS;

EID: 55549133272     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.5563     Document Type: Article

References (36)

1. Horwitz M: The genetics of familial leukemia. Leukemia 11:1347-1359, 1997
2. Song WJ, Sullivan MG, Legare RD, et al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23:166-175, 1999
3. Smith ML, Cavenagh JD, Lister TA, et al: Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351:2403-2407, 2004
4. Tenen DG: Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 3:89-101, 2003
5. Rosenbauer F, Tenen DG: Transcription factors in myeloid development: Balancing differentiation with transformation. Nat Rev Immunol 7:105-117, 2007
6. Zhang DE, Zhang P, Wang ND, et al: Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein α-deficient mice. Proc Natl Acad Sci USA 94:569-574, 1997
7. Zhang P, Iwasaki-Arai J, Iwasaki H, et al: Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBPα. Immunity 21:853-863, 2004
8. Pabst T, Mueller BU, Zhang P, et al: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukaemia. Nat Genet 27:263-270, 2001
9. Gombart AF, Hofmann WK, Kawano S, et al: Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias. Blood 99:1332-1340, 2002
10. Preudhomme C, Sagot C, Boissel N, et al: Favourable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 100:2717-2723, 2002
11. Van Waalwijk B, van Doorn-Khosorvani S, Erpelinck C, et al: Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 4:31-40, 2003
12. Snaddon J, Smith ML, Neat M, et al: Mutations of CEBPA in acute myeloid leukaemia FAB types M1 and M2. Genes Chromosomes Cancer 37:72-78, 2003
13. Lin LI, Chen CY, Lin DT, et al: Characterization of CEBPA mutations in acute myeloid leukemia: Most patients with CEBPA mutations have biallelic mutations and show distinct immunophenotype of the leukemic cells. Clin Cancer Res 11:1372-1379, 2005
14. Bienz M, Ludwig M, Mueller BU, et al: Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 11:1416-1424, 2005
15. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Identification of prognostically relevant genotypes and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
16. Nerlov C: C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev 4:394-400, 2004
17. Sellick GS, Spendlove HE, Catovsky D, et al: Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukemia. Leukemia 19:1276-1278, 2005
18. Nanri T, Uike N, Kawakita T, et al: A pedigree harboring a germ-line N-terminal C/EBPBalpha mutation and development of acute myeloblastic leukemia with a somatic C-terminal C/EBPalpha mutation. Blood 108:1916a, 2006 (abstr)
19. Löwenberg B, van Putten W, Theobald M, et al: Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349:743-752, 2003
20. Pabst T, Schwaller J, Tobler A, et al: Detection of microsatellite markers in leukaemia using DNA from archival bone marrow smears. Br J Haematol 95:135-137, 1996
21. Pabst T, Schwaller J, Bellomo MJ, et al: Frequent clonal loss of heterozygosity but scarcity of microsatellite instability at chromosomal breakpoint cluster regions in adult leukemias. Blood 88:1026-1034, 1996
22. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005
23. Schnittger S, Kohl TM, Haferlach T, et al: KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 107:1791-1799, 2006
24. Pabst T, Mueller BU: Transcriptional dysregulation during myeloid transformation in AML. Oncogene 26:6829-6837, 2007
25. Mengis C, Aebi S, Tobler A, et al: Assessment of differences in patient populations selected for or excluded from participation in clinical phase III acute myelogenous leukemia trials. J Clin Oncol 21:3933-3939, 2003
26. Mueller BU, Pabst T: CEBPA and the pathophysiology of acute myeloid leukemia (AML). Curr Opin Hematol 13:7-14, 2006
27. Janov AJ, Leong T, Nathan DG, et al: Diamond-Blackfan anemia: Natural history and sequelae of treatment. Medicine (Baltimore) 75:77-78, 1996
28. Donadieu J, Leblanc T, Bader Meunier B, et al: Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia: Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 90:45-53, 2005
29. Woods WG, Roloff JS, Lukens JN, et al: The occurrence of leukemia in patients with the Shwachman syndrome. J Pediatr 99:425-428, 1981
30. Dokal I: Dyskeratosis congenita in all its forms. Br J Haematol 110:768-779, 2000
31. Kutler DI, Singh B, Satagopan J, et al: A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101:1249-1256, 2003
32. Aktas D, Koc A, Boduroglu K, et al: Myelodysplastic syndrome associated with monosomy 7 in a child with Bloom syndrome. Cancer Genet Cytogenet 116:44-46, 2000
33. Imamura J, Miyoshi I, Koeffler HP: p53 in hematologic malignancies. Blood 84:2412-2421, 1994
34. Ravindranath Y: Down syndrome and leukemia: New insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer 44:1-7, 2005
35. Perry C, Eldor A, Soreq H: Runx1/AML1 in leukemia: Disrupted association with diverse protein partners. Leuk Res 26:221-228, 2002
36. Harada H, Harada Y, Niimi H, et al: High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103:2316-2324, 2004